Neumora Advances to Phase III with Depression Drug, Hires AbbVie Vet as CEO

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

A New Way to Treat Depression: Barry Greene on The Long Run
Neumora Snaps Up $112M to Advance Precision Neuroscience Work Through Clinic
Neumora Secures $500M, Amgen Deal, in Quest for Precision Neuroscience R&D